BeOne Medicines Ltd. — Director's Dealing 2018

Mar 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2018-02-28

Reporting Person: Li Ji (EVP and Gl. Head of Bus. Dev.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-28	American Depositary Shares	M	10000	$26.65	Acquired	10000	Direct
2018-02-28	American Depositary Shares	S	1749	$143.7170	Disposed	8251	Direct
2018-02-28	American Depositary Shares	S	1100	$144.7766	Disposed	7151	Direct
2018-02-28	American Depositary Shares	S	1400	$145.9652	Disposed	5751	Direct
2018-02-28	American Depositary Shares	S	1800	$146.9156	Disposed	3951	Direct
2018-02-28	American Depositary Shares	S	1551	$148.6629	Disposed	2400	Direct
2018-02-28	American Depositary Shares	S	2400	$149.4871	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-28	Share Option (Right to Buy)	$2.05	M	130000	Disposed	2026-05-02	Ordinary Shares (2246000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	475000	Direct

Footnotes

F1: Each American Depositary Share represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.50 to $144.49, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.50 to $145.39, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.56 to $146.26, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.61 to $147.36, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.08 to $149.03, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.14 to $150.11, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F9: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.

F10: These securities vest over a four-year period as follows: 25% on the first anniversary of May 3, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter.